Novartis Cosentyx Becomes First and Only FDA-Approved Anti-IL-17 Biologic for People with Polymyalgia Rheumatica

Nov 18, 2026 - 03:00
 0  0
Basel, November 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0